Intelsat Completes Satellite Life-Extension Mission, Makes Space History
MCLEAN, Va.--(BUSINESS WIRE)--Apr 9, 2025--
Intelsat, operator of one of the world's largest integrated satellite and terrestrial networks, became the first and only satellite operator to complete a life-extension mission adding five years of valuable service to the Intelsat 901 (IS-901) satellite and its many customers, providing extended reliable and global connectivity.
This press release features multimedia. View the full release here:
Mission Extension Vehicle 1 (MEV-1) safely departs from Intelsat 901 (IS-901) in the Geosynchronous Earth Orbit (GEO) after providing five years of life extension service. The earth is visible in the background as well as MEV-1's docking mechanism on the right. (Courtesy: Northrop Grumman's Space Logistics).
' The MEV mission proved that in-orbit servicing enhances satellite sustainability and efficiency in space,' said Jean-Luc Froeliger, SVP of Space Systems, Intelsat. 'We were able to provide five additional years of reliable service to our Network, Media and Mobility customers and paved the way for future advancements in satellite servicing.'
The world's first Mission Extension Vehicle (MEV), developed by Northrop Grumman Corporation's (NYSE: NOC) Space Logistics LLC, successfully detached from IS-901 after moving the satellite to the graveyard orbit, where the satellite will be decommissioned after nearly 24 years of service. The MEV first docked with IS-901 in February of 2020 nearly 19 years after the satellite was first launched.
Geostationary satellites use propellant to remain at a specific orbital location, relocate to a new location or eventually be moved to a graveyard orbit. The MEV has its own propellant and thrusters that operate independently of the satellite. Through in-orbit docking, the MEV allows Intelsat to extend the life of a satellite by several years when the original propellant of that satellite has been depleted.
'Using the MEV to extend the life of IS-901 was a great commercial success for our customers, as well as a historic technical achievement,' Froeliger said. 'We had to do a rendezvous and approach of two spacecraft moving at 3km per second,' Froeliger said.
Following this success, Intelsat partnered with Northrop Grumman on a second mission in 2021, using MEV-2 to extend the life of Intelsat 10-02, a combination that remains operational today. Intelsat continues to seek out and invest in next-generation satellite life-extension projects and other innovation setting the stage for continued advancements and enabling emerging space companies to shape the future of the industry.
About Intelsat
Intelsat's global team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company's next-generation worldwide network and managed services. Bridging the digital divide by operating one of the world's largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry 'firsts' in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the 'next firsts' in space as they disrupt the field and lead in the digital transformation of the industry.
Twitter/X
YouTube
Melissa Longo [email protected]; +1 240-308-1881
SOURCE: Intelsat
Copyright Business Wire 2025.
PUB: 04/09/2025 11:48 AM/DISC: 04/09/2025 11:48 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
- Composition of matter patent affirmed, provides protection into 2030 - Builds on recent ruling in favor of Acadia for formulation patent expiring in 2038 SAN DIEGO, June 09, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent established in Allergan USA, Inc. v. MSN Laboratories Private Ltd., MSN Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, holding that "a first filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date." "We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for NUPLAZID, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for NUPLAZID 34 mg capsule formulation into 2038," said Catherine Owen Adams, Chief Executive Officer. "These decisions reinforce our commitment to safeguarding the intellectual property that underpins our innovations in addressing serious, unmet medical needs." This follows the U.S. District Court for the District of Delaware ruling in favor of Acadia regarding its '721 formulation patent for NUPLAZID which ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New Drug Application) filers. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," "continue" and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the impact of the court ruling on our business and our ability to defend ourselves in the future; (ii) the continued patent protection for NUPLAZID; and (iii) the anticipated timing for termination of such protections. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our ability to maintain, protect and enhance our intellectual property; the outcome of other existing and potential future lawsuits challenging our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-Q for the quarter ended March 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law. View source version on Contacts Investor Contacts: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Media Contact: Acadia Pharmaceuticals Kazenelson(818) 395-3043media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
UPI
38 minutes ago
- UPI
CPAP or Zepbound? Patients, doctors debate sleep apnea treatment
Doctors favor treatment with continuous positive airway pressure, or CPAP, machines, researchers are slated to report this week at a meeting of the American Academy of Sleep Medicine. Adobe stock June 9 (UPI) A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study reports. Doctors favor treatment with continuous positive airway pressure, or CPAP, machines, researchers are slated to report this week at a meeting of the American Academy of Sleep Medicine. The machines keep airways open using mild air pressure provided through a mask patients wear while sleeping. But patients would rather treat their sleep apnea with tirzepatide (Zepbound), a GLP-1 weight-loss drug, researchers found. "The results highlight a need for real-world comparative effectiveness data of CPAP versus tirzepatide, and a potential mismatch between patient and provider preferences when managing comorbid obesity and obstructive sleep apnea," lead researcher Ahmed Khalaf said in a news release. He's a sleep technician in the pulmonary, critical care and sleep medicine division at University of California-San Diego. Nearly 30 million adults in the United States have sleep apnea, a disease in which the upper airway collapses during sleep, causing people to wake repeatedly. CPAP has been considered the gold standard for treating sleep apnea, but some patients find the machines too bulky and noisy. About 50% of people prescribed CPAP either can't use it often enough to matter or find it too bothersome, according to Harvard Medical School. Common problems include mask discomfort, dry mouth, breathing that feels out of sync and noise from the machine. Late last year, the U.S. Food and Drug Administration approved Zepbound as the first drug to treat people with obesity and sleep apnea. At the time, the sleep medicine society hailed the approval as "a positive development for patients and clinicians, who now have another treatment option for this sleep disorder," according to a statement from the academy. But Zepbound is only for people with obesity and sleep apnea, the society noted. Also, Zepbound can reduce the severity of sleep apnea through weight loss, but might not cure the problem. For the new study, researchers analyzed nationwide online survey data from 365 patients, and also spoke to 17 sleep medicine professionals at UCSD. Doctors favored CPAP over Zepbound 53% to 26%, while patients favored Zepbound over CPAP 48% to 35%. Both doctors and patients supported treatment that combined CPAP and Zepbound, but doctors were more enthusiastic about combination therapy, 88% versus 61%. The patients' preferences are likely driven by their own experiences -- 78% said they were either current or former users of CPAP, results show. By comparison, only 23% of patients said they'd ever used Zepbound or Ozempic (semaglutide), the other prominent GLP-1 drug. Principal investigator Dr. Chris Schmickl, an assistant professor of medicine at University of California-San Diego, expressed surprise at the level of disagreement between patients and providers. "Recognizing differing attitudes toward treatment is crucial for developing a realistic and achievable action plan," he said in a news release. "Additional research to understand the underlying reasons behind these preferences will offer valuable insights for providers to guide treatment decisions." Researchers are scheduled to present these findings Wednesday at the society meeting in Seattle. Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. More information Harvard Medical School has more on managing CPAP problems. Copyright © 2025 HealthDay. All rights reserved.
Yahoo
43 minutes ago
- Yahoo
Civeo Announces a 4-Year Contract Renewal in the Australian Bowen Basin with expected revenues of approximately A$250 million
HOUSTON & SYDNEY, June 09, 2025--(BUSINESS WIRE)--Civeo Corporation (NYSE: CVEO) today announced that it was awarded a four-year contract renewal with a leading metallurgical coal producer to provide rooms and hospitality services from the Company's existing Coppabella, Moranbah and Nebo villages in the Australian Bowen Basin. The contract renewal is expected to generate approximately A$250 million in total revenues from 2025 to 2029. This contract renewal was contemplated in Civeo's latest full year 2025 revenue and Adjusted EBITDA guidance. "We appreciate our customer's continued trust in Civeo's operations and look forward to continuing to build on our longstanding relationship throughout this contract term and beyond. Our ability to provide room supply surety at a large scale with a consistent service offering at a competitive price to the customer's multiple mining locations is unmatched in the marketplace. This contract renewal during a period of softness in the met coal markets is a testament to the strength of our value proposition throughout the commodity cycle," said Bradley J. Dodson, President and Chief Executive Officer. About Civeo Civeo Corporation is a leading provider of hospitality services with prominent market positions in the Australian natural resource regions and the Canadian oil sands. Civeo offers comprehensive solutions for lodging hundreds or thousands of workers with its long-term and temporary accommodations and provides food services, housekeeping, facility management, laundry, water and wastewater treatment, power generation, communications systems, security and logistics services. Civeo currently owns and operates a total of 28 lodges and villages in Australia and North America with an aggregate of approximately 27,500 rooms. In addition, Civeo operates and provides hospitality services at 24 customer-owned locations with more than 19,000 rooms. Civeo is publicly traded under the symbol CVEO on the New York Stock Exchange. For more information, please visit Civeo's website at Forward Looking Statements Statements included in this release regarding this contract award, the expected benefits and contracted revenue visibility and other statements that are not historical facts, are forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933). Forward-looking statements include words or phrases such as "anticipate," "believe," "contemplate," "estimate," "expect," "intend," "plan," "project," "could," "may," "might," "should," "will" and words and phrases of similar import. The forward-looking statements included herein are based on current expectations and entail various risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Risks and uncertainties with respect to forward-looking statements included herein include, among other things, risks associated with the ability of Civeo to implement its plans, forecasts and other expectations with respect to this contract, risks associated with the general nature of the accommodations industry (including lower than expected room requirements), risks associated with the level of supply and demand for oil, coal, natural gas, iron ore and other minerals, including the level of demand for coal and other natural resources from Australia, and fluctuations in the current and future prices of oil, coal, natural gas, iron ore and other minerals, risks associated with currency exchange rates, risks associated with the development of new projects, including whether such projects will continue in the future, and other factors discussed in the "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" sections of Civeo's annual report on Form 10-K for the year ended December 31, 2024 and other reports Civeo may file from time to time with the U.S. Securities and Exchange Commission. Each forward-looking statement contained in this release speaks only as of the date of this release. Except as required by law, Civeo expressly disclaims any intention or obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts Regan NielsenCiveo CorporationVice President, Corporate Development & Investor Relations713-510-2400
